These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 22103888)

  • 21. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.
    Haas M; Heinemann V; Kullmann F; Laubender RP; Klose C; Bruns CJ; Holdenrieder S; Modest DP; Schulz C; Boeck S
    J Cancer Res Clin Oncol; 2013 Apr; 139(4):681-9. PubMed ID: 23315099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
    Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
    BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of third-line chemotherapy in recurrent or metastatic gastric cancer: A cohort study with propensity score matching analysis.
    Choi YW; Ahn MS; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Sheen SS
    Medicine (Baltimore); 2018 Sep; 97(39):e12588. PubMed ID: 30278571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation between expression of thymidylate synthase and clinical outcome of advanced gastric cancer treated with capecitabine alone chemotherapy.
    Liu XF; Zhang H; Sun JQ; Yin C; Liu TF; Yang H; Chen LH
    Tumour Biol; 2014 Dec; 35(12):12409-14. PubMed ID: 25185651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study.
    Inal A; Kaplan MA; Kuçukoner M; Urakci Z; Guven M; Nas N; Yunce M; Işikdogan A
    Asian Pac J Cancer Prev; 2012; 13(8):3869-72. PubMed ID: 23098485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative analysis of the efficacy and safety of oxaliplatin plus 5-fluorouracil/leucovorin (modified FOLFOX6) with advanced gastric cancer patients having a good or poor performance status.
    Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Esenkaya A; Uzunoglu S; Cicin I
    Asian Pac J Cancer Prev; 2015; 16(6):2355-9. PubMed ID: 25824764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is chemotherapy in elderly patients with metastatic or recurrent gastric cancer as tolerable and effective as in younger patients?
    Kim ST; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):194-200. PubMed ID: 22524579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of intraperitoneal and intravenous chemotherapy for advanced gastric cancer with peritoneal metastasis.
    Chen Y; Wang XJ; Lin RB; Chen L; Lin G; Guo ZQ
    Tumori; 2014; 100(5):e180-8. PubMed ID: 25343556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma.
    Lee VHF; Kwong DLW; Lam KO; Lai YC; Li Y; Tong CC; Ho PPY; Chan WL; Wong LS; Leung DKC; Chan SY; Chan FT; Leung TW; Lee AWM
    Medicine (Baltimore); 2017 Apr; 96(15):e6518. PubMed ID: 28403082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination versus single-agent as palliative chemotherapy for gastric cancer.
    Choi JH; Choi YW; Kang SY; Jeong GS; Lee HW; Jeong SH; Park JS; Ahn MS; Sheen SS
    BMC Cancer; 2020 Mar; 20(1):167. PubMed ID: 32122320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy.
    Kanagavel D; Pokataev IA; Fedyanin MY; Tryakin AA; Bazin IS; Narimanov MN; Yakovleva ES; Garin AM; Tjulandin SA
    Ann Oncol; 2010 Sep; 21(9):1779-1785. PubMed ID: 20150573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Individualized Chemotherapy for Metastatic Gastric Cancer: Retrospective Data from a University Hospital in Brazil.
    Aguiar Junior PN; Ribas C; Forones NM
    Asian Pac J Cancer Prev; 2015; 16(13):5289-96. PubMed ID: 26225668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models.
    Koo DH; Ryoo BY; Kim HJ; Ryu MH; Lee SS; Moon JH; Chang HM; Lee JL; Kim TW; Kang YK
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):913-21. PubMed ID: 21290247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
    Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK
    Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy.
    Fukuda H; Takagi T; Kondo T; Yoshida K; Shimizu S; Nagashima Y; Tanabe K
    Int J Clin Oncol; 2018 Jun; 23(3):539-546. PubMed ID: 29302841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
    Kang EJ; Im SA; Oh DY; Han SW; Kim JS; Choi IS; Kim JW; Kim YJ; Kim JH; Kim TY; Lee JS; Bang YJ; Lee KW
    Gastric Cancer; 2013 Oct; 16(4):581-9. PubMed ID: 23266882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Systemic Inflammatory Response and Nutritional Biomarkers as Predictive Factors in Patients with Recurrent Gastric Cancer.
    Namikawa T; Yokota K; Yamaguchi S; Iwabu J; Munekage M; Uemura S; Tsujii S; Maeda H; Kitagawa H; Kumon M; Kobayashi M; Hanazaki K
    Oncology; 2020; 98(7):452-459. PubMed ID: 32182616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is hypoalbuminemia an independent prognostic factor in patients with gastric cancer?
    Crumley AB; Stuart RC; McKernan M; McMillan DC
    World J Surg; 2010 Oct; 34(10):2393-8. PubMed ID: 20602101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of Markers of Systemic Inflammation for Predicting Survival and Chemotherapeutic Outcomes and Monitoring Tumor Progression in Patients with Unresectable Metastatic Colorectal Cancer.
    Shibutani M; Maeda K; Nagahara H; Ohtani H; Sakurai K; Yamazoe A; Kimura K; Toyokawa T; Amano R; Kubo N; Tanaka H; Muguruma K; Ohira M; Hirakawa K
    Anticancer Res; 2015 Sep; 35(9):5037-46. PubMed ID: 26254405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS).
    Ryu MH; Baba E; Lee KH; Park YI; Boku N; Hyodo I; Nam BH; Esaki T; Yoo C; Ryoo BY; Song EK; Cho SH; Kang WK; Yang SH; Zang DY; Shin DB; Park SR; Shinozaki K; Takano T; Kang YK;
    Ann Oncol; 2015 Oct; 26(10):2097-101. PubMed ID: 26216386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.